GSK (NYSE:GSK) Announces Earnings Results

GSK (NYSE:GSK) issued its earnings results on Wednesday. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15, Zacks reports. GSK had a return on equity of 50.62% and a net margin of 7.97%. GSK updated its FY 2025 guidance to 2.090-2.130 EPS.

GSK Price Performance

GSK stock traded down $0.69 during midday trading on Thursday, hitting $37.01. The company’s stock had a trading volume of 2,390,836 shares, compared to its average volume of 4,433,834. The firm has a market capitalization of $76.71 billion, a price-to-earnings ratio of 24.02, a price-to-earnings-growth ratio of 1.38 and a beta of 0.64. GSK has a 12 month low of $31.72 and a 12 month high of $45.92. The company has a 50 day moving average of $34.17 and a two-hundred day moving average of $37.60. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.